BioAge Labs (NASDAQ:BIOA – Get Free Report) and Sol-Gel Technologies (NASDAQ:SLGL – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations and institutional ownership.
Institutional and Insider Ownership
26.2% of Sol-Gel Technologies shares are held by institutional investors. 17.6% of BioAge Labs shares are held by company insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares BioAge Labs and Sol-Gel Technologies”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BioAge Labs | $8.99 million | 25.97 | -$80.61 million | ($2.55) | -1.99 |
| Sol-Gel Technologies | $19.39 million | 8.84 | -$6.13 million | ($5.23) | -10.02 |
Sol-Gel Technologies has higher revenue and earnings than BioAge Labs. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than BioAge Labs, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
BioAge Labs has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Comparatively, Sol-Gel Technologies has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500.
Profitability
This table compares BioAge Labs and Sol-Gel Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioAge Labs | -1,253.60% | -31.42% | -29.59% |
| Sol-Gel Technologies | -1,115.39% | -38.80% | -33.29% |
Analyst Ratings
This is a summary of recent ratings and target prices for BioAge Labs and Sol-Gel Technologies, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioAge Labs | 1 | 1 | 6 | 0 | 2.62 |
| Sol-Gel Technologies | 1 | 0 | 4 | 2 | 3.00 |
BioAge Labs currently has a consensus price target of $33.00, indicating a potential upside of 549.61%. Sol-Gel Technologies has a consensus price target of $197.50, indicating a potential upside of 276.98%. Given BioAge Labs’ higher possible upside, equities analysts plainly believe BioAge Labs is more favorable than Sol-Gel Technologies.
Summary
Sol-Gel Technologies beats BioAge Labs on 8 of the 15 factors compared between the two stocks.
About BioAge Labs
BioAge Labs is a clinical-stage biopharmaceutical company developing medicines for metabolic diseases by targeting biological pathways associated with aging. Its research platform draws on human data to identify age-related mechanisms that may be relevant to disease and treatment. The company’s pipeline includes BGE-102, an investigational oral inhibitor of the NLRP3 protein, which is being developed for metabolic conditions. BioAge previously studied azelaprag, an apelin-receptor agonist, but discontinued its development after safety concerns arose in a clinical trial.
About Sol-Gel Technologies
Sol-Gel Technologies is an Israel-based dermatology company that develops topical treatments for skin conditions. Its proprietary technology uses silica-based microencapsulation to formulate active ingredients for topical use. The company’s products include Epsolay, a benzoyl peroxide cream approved in the United States for inflammatory lesions of rosacea, and Twyneo, a topical combination of tretinoin and benzoyl peroxide approved for acne vulgaris. Sol-Gel has pursued commercialization and licensing opportunities in the United States and other markets.
Receive News & Ratings for BioAge Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioAge Labs and related companies with MarketBeat.com's FREE daily email newsletter.
